Prakt. lékáren. 2011; 7(2): 58-61

The irreplaceable role of vitamin D in prevention and treatment of osteoporosis

prof.MUDr.Sylvie Dusilová Sulková, DrSc., MBA
Klinika nefrologie IKEM, Praha

Osteoporosis and its consequences represent a major clinical and socio-economic problem. A low calcium intake and particularly vitamin

D deficiency are the crucial factors resulting in or contributing to osteoporosis; supplementation with vitamin D is an essential

condition for both prevention and treatment. Calcidiol concentrations below 50 nmol/l (= 20 ng/ml) are clearly unfavourable for bone

metabolism; some authors extend this limit up to 70 nmol/l. Vitamin D3 (cholecalciferol) at 700–800 IU daily is the preferred type of

vitamin D supplementation. Attention also has to paid to the minerals essential for bone tissue (daily calcium intake of 800–1 000 mg,

or even as high as 1 500 mg). Normalization of vitamin D levels in the body is beneficial for the skeletal muscle, immune system and

many other tissues.

Keywords: vitamin D, osteoporosis, calcium, calcidiol, calcitriol, hyperparathyroidism

Published: April 5, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dusilová Sulková S. The irreplaceable role of vitamin D in prevention and treatment of osteoporosis. Praktické lékárenství. 2011;7(2):58-61.
Download citation

References

  1. Štěpán J. Farmakoterapie osteoporózy I: vápník, vitamin D, hormonální léčba, selektivní modulátory receptorů pro estrogeny a stroncium ranelát. Prakt. lékáren. 2009; 5: 168-171.
  2. Štěpán J. Farmakoterapie osteoporózy II: aminobisfosfonáty, kalcitonin, teriparatid a parathormon. Prakt. lékáren. 2009; 5: 210-213.
  3. Shoback D. Update in osteoporosis and metabolic bone disorder. J Clin Endocrin Metab 2007; 92: 747-753. Go to original source... Go to PubMed...
  4. Palička V, Pohlídal A, Živný V. Terapie osteoporózy. Intern Med 2008; 8: 382-398.
  5. Avenell A, Gillespie W, Gillespie LD, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Databáze Syst Rev 2009; 15(2): CD000227.
  6. Lips P, Bouillon R, van Schoor N, et al. Reducing fracture risk with calcium and vitamin D. Clin Endocrin 2010; 73: 277-285. Go to original source... Go to PubMed...
  7. Bischoff-Ferrari HA, Willett WC, Wong JH, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 2009; 169: 551-561. Go to original source... Go to PubMed...
  8. Rizzoli R, Boomem S, Brandi ML, et al. The role of calcium and vitamin D in the management of osteoporosis. Bone 2008; 42: 246-249. Go to original source... Go to PubMed...
  9. van den Bergh JPW, Bours SPG. Optimal use of vitamin D when treating osteoporosis. Curr Osteopor Rep 2010; doi 10.1007/sl1914-010-0041-0. Go to original source... Go to PubMed...
  10. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281. Go to original source... Go to PubMed...
  11. Dusso A, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-F28. Go to original source... Go to PubMed...
  12. Courbeibaisse M, Souberbielle JC, Thervet E. Potential nonclassical effects of vitamin D in transplant recipients. Transplantation 2010; 89: 131-137. Go to original source... Go to PubMed...
  13. Sochorová K, Bartůňková J. Vitamin D a imunitní systém. Teorie a vlastní zkušenosti. Intern Med 2007; 1: 28-30.
  14. Sulková S, Fořtová M, Uhrová J, et al. Význam stanovení hladin metabolitů vitaminu D u pacientů s poruchou funkce ledvin. Vnitř Lék 2004; 50: 510-518. Go to PubMed...
  15. Dusilová Sulková S. Vitamin D metabolism and vitamin D: traditional and nontraditional target organs: implications for kidney patients. J Ren Care 2009; 35(Suppl 1): 39-44. Go to original source... Go to PubMed...
  16. Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc 2002; 77: 453-468. Go to original source...
  17. Heaney RP. Long-latency deficiency disease: insights from calcium and vitamin D. Am J Clin Nutr 2003; 78: 912-919. Go to original source... Go to PubMed...
  18. Bischoff-Ferrari HA, Ditrich T, Orav EJ, et al. Higher 25hydroxyvitamin D concentrations are associated with better lower extremity function in both active and inactive persóna aged ? 60 y. Am J Clin Nutr 2004; 80: 752-758. Go to original source... Go to PubMed...
  19. Bischoff-Ferrari HA, Kiel DP, Dawson-Hughes B, et al. Dietary calcium and serum 25-hydroxyvitamin D status in relation to BMD among US adults. J Bone Miner Res 2009; 24: 935-942. Go to original source... Go to PubMed...
  20. Dusilová Sulková S, a kol. Renální osteopatie. Maxdorf Jessenius 2007.
  21. Ishijima M, Sakamoto Y, Yamanaka M, et al. Minimum required vitamin D level for optimal increase in bone mineral density with alednronate treatment in osteoporotic women. Calcif Tissue Int 2009. Go to original source...
  22. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008; 88(Suppl): S582-S586. Go to original source... Go to PubMed...
  23. Barone A, Guisti A, Pioli G, et al. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. J Am Geriatr Soc 2007; 55: 752-757. Go to original source... Go to PubMed...
  24. Schacht E, Dukas L, Richy F. Combined therapies in osteoporosis: bisphosponates and vitamin D hormone analogs. J Muskuloskelet Neuronal Interact 2007; 7: 174-184.
  25. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010; 341: c3691. Go to original source... Go to PubMed...




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.